Nice Insight’s Top Companies lists are comprised of the highest scoring companies, as rated by buyers of outsourced services, with respect to customer perception within each category. Customer perception describes how a current buyer or prospect rates a company based on the information they have been exposed to—from marketing materials to word-of-mouth influence, as well as experience with the company. Nice Insight uses six key drivers of outsourcing—quality, reliability, productivity, affordability, innovation and regulatory history—to measure customer perception; the number listed is the average of the six individual scores, down to the decimal point.
CRO Preclinical
| Analytical Services | Overall CP | |
|---|---|---|
| 1 | Eurofins Lancaster | 92.80% |
| 2 | Surpass | 90.00% |
| 3 | Huntingdon Life Sciences | 89.13% |
| 4 | Frontage | 88.33% |
| 5 | QPS | 87.17% |
| 6 | BASi | 87.00% |
| 6 | Sannova Analytical | 87.00% |
| 8 | Product Safety Labs | 86.00% |
| 9 | Algorithme | 85.50% |
| 10 | Covance | 85.40% |
| 10 | Quintiles | 85.40% |
| BioAnalytical Services | Overall CP | |
|---|---|---|
| 1 | Product Safety Labs | 93.37% |
| 2 | Ricerca | 92.83% |
| 3 | Covance | 90.57% |
| 4 | Frontage | 90.00% |
| 5 | Charles River | 89.53% |
| 6 | QPS | 89.33% |
| 7 | Eurofins Lancaster | 88.90% |
| 8 | Huntingdon Life Sciences | 88.33% |
| 9 | Worldwide Clinical Trials | 87.63% |
| 10 | Seventh Wave | 87.57% |
| 10 | Sannova Analytical | 87.57% |
| Toxicology | Overall CP | |
|---|---|---|
| 1 | Sannova Analytical | 88.33% |
| 2 | Huntingdon Life Sciences | 87.20% |
| 3 | BASi | 86.67% |
| 4 | Frontage | 85.73% |
| 5 | Toxikon | 85.53% |
| 6 | MicroConstants | 84.30% |
| 7 | BRI | 81.67% |
| 7 | SNBL | 81.67% |
| 9 | Product Safety Labs | 81.33% |
| 10 | QPS | 81.00% |
| Pharmacovigilance | Overall CP | |
|---|---|---|
| 1 | Worldwide Clinical Trials | 90.00% |
| 2 | Quintiles | 87.50% |
| 3 | Huntingdon Life Sciences | 86.67% |
| 4 | MPI Research | 82.00% |
| 5 | Algorithme | 81.13% |
| 6 | Frontage | 81.11% |
| 6 | SNBL | 81.11% |
| 8 | Tandem Labs | 80.56% |
| 9 | QPS | 79.33% |
| 10 | Charles River | 78.06% |
| Analytical Services | Overall CP | |
|---|---|---|
| 1 | Eurofins Lancaster | 92.80% |
| 2 | Clinlogix | 89.63% |
| 3 | SGS | 89.20% |
| 4 | Frontage | 88.33% |
| 5 | QPS | 87.17% |
| 6 | Sannova Analytical | 87.00% |
| 7 | Chiltern | 86.70% |
| 8 | Parexel | 86.40% |
| 9 | PPD | 85.86% |
| 10 | Covance | 85.40% |
| 10 | Quintiles | 85.40% |
| BioAnalytical Services | Overall CP | |
|---|---|---|
| 1 | Covance | 90.56% |
| 2 | Frontage | 90.00% |
| 2 | SGS | 90.00% |
| 4 | Charles River | 89.53% |
| 5 | QPS | 89.33% |
| 6 | Eurofins Lancaster | 88.90% |
| 7 | Clinlogix | 88.33% |
| 8 | CNS | 88.00% |
| 9 | Worldwide Clinical Trials | 87.63% |
| 10 | Sannova Analytical | 87.56% |
| Clinical Monitoring | Overall CP | |
|---|---|---|
| 1 | Clinlogix | 89.06% |
| 2 | Parexel | 86.67% |
| 3 | PRA | 86.33% |
| 4 | Celerion | 85.46% |
| 5 | Rho | 85.13% |
| 6 | Medsource | 84.83% |
| 7 | QPS | 84.33% |
| 8 | SynteractHCR | 84.03% |
| 9 | SNBL | 84.00% |
| 10 | Novotech | 83.83% |
| Clinical Research | Overall CP | |
|---|---|---|
| 1 | INC Research | 93.33% |
| 2 | Parexel | 85.97% |
| 3 | Celerion | 85.83% |
| 4 | Intertek | 85.30% |
| 5 | Clinlogix | 84.90% |
| 6 | Vince & Associates | 83.30% |
| 7 | Bioskin | 83.00% |
| 8 | InnoPharma | 82.83% |
| 9 | SanaClis | 82.80% |
| 10 | SGS | 82.26% |
Relevant
news
marketing@medicilon.com
